Kneshay Harper

Intrapatient comparative analysis of tumor-informed ctDNA and ctHPV-DNA in patients with HPV-driven OPSCC.

Evgeny Izumchenko, Hillary S. Sloane, Daniel L. Edelstein, Kneshay Harper et autres

6075 Background: The rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) is largely attributable to human papillomavirus associated (HPV+) disease, which accounts for ~70% of OPSCC cases. Circulating tumor (ct)DNA has the potential to enable more accurate treatment response assessment, guide response-adaptive …

us (code pays fourni par la source)

Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC).

Harrison David Winters, Thanh J. Nguyen, Reena S. Suresh, Ervin Griffin et autres

30 Background: While many patients with LARC experience durable responses after TNT, relapse risk remains a concern and is not reliably predicted by standard clinicopathologic measures. ctDNA is a promising biomarker for minimal residual disease (MRD) that could improve post-TNT risk-stratification and …

us (code pays fourni par la source)

Data from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Linda K. Zane, Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar et autres

AbstractPurpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection …